|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.2 HKD | -1.48% |
|
-11.11% | -22.34% |
| Apr. 17 | Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer | CI |
| Apr. 02 | Hutchmed endometrial cancer treatment application accepted for review | AN |
Innovent Biologics, Inc. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 2,239.6 million compared to CNY 1,941.75 million a year ago. Net loss was CNY 950.47 million compared to CNY 1,003.56 million a year ago.
Basic loss per share from continuing operations was CNY 0.65 compared to CNY 0.69 a year ago. Diluted loss per share from continuing operations was CNY 0.65 compared to CNY 0.69 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -22.34% | 6.98B | |
| -5.99% | 84.46B | |
| +2.76% | 40.85B | |
| -24.88% | 27.69B | |
| +53.61% | 24.28B | |
| -8.08% | 17.09B | |
| -33.74% | 13.67B | |
| -16.63% | 11.86B | |
| -11.19% | 11.79B | |
| -2.25% | 8.07B |
INNOVENT BIOLOGICS, INC. 
